181 related articles for article (PubMed ID: 19001108)
1. Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.
Cihlar T; Laflamme G; Fisher R; Carey AC; Vela JE; Mackman R; Ray AS
Antimicrob Agents Chemother; 2009 Jan; 53(1):150-6. PubMed ID: 19001108
[TBL] [Abstract][Full Text] [Related]
2. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.
Cihlar T; Ray AS; Laflamme G; Vela JE; Tong L; Fuller MD; Roy A; Rhodes GR
Antivir Ther; 2007; 12(2):267-72. PubMed ID: 17503669
[TBL] [Abstract][Full Text] [Related]
3. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).
Uwai Y; Ida H; Tsuji Y; Katsura T; Inui K
Pharm Res; 2007 Apr; 24(4):811-5. PubMed ID: 17372702
[TBL] [Abstract][Full Text] [Related]
4. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs.
Cihlar T; Ho ES; Lin DC; Mulato AS
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):641-8. PubMed ID: 11563082
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1.
Ho ES; Lin DC; Mendel DB; Cihlar T
J Am Soc Nephrol; 2000 Mar; 11(3):383-393. PubMed ID: 10703662
[TBL] [Abstract][Full Text] [Related]
6. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.
Cihlar T; Lin DC; Pritchard JB; Fuller MD; Mendel DB; Sweet DH
Mol Pharmacol; 1999 Sep; 56(3):570-80. PubMed ID: 10462545
[TBL] [Abstract][Full Text] [Related]
7. Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.
Cihlar T; Ray AS; Boojamra CG; Zhang L; Hui H; Laflamme G; Vela JE; Grant D; Chen J; Myrick F; White KL; Gao Y; Lin KY; Douglas JL; Parkin NT; Carey A; Pakdaman R; Mackman RL
Antimicrob Agents Chemother; 2008 Feb; 52(2):655-65. PubMed ID: 18056282
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of active renal tubular efflux of tenofovir.
Ray AS; Cihlar T; Robinson KL; Tong L; Vela JE; Fuller MD; Wieman LM; Eisenberg EJ; Rhodes GR
Antimicrob Agents Chemother; 2006 Oct; 50(10):3297-304. PubMed ID: 17005808
[TBL] [Abstract][Full Text] [Related]
9. Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates.
Mandíková J; Volková M; Pávek P; Česnek M; Janeba Z; Kubíček V; Trejtnar F
Toxicology; 2013 Sep; 311(3):135-46. PubMed ID: 23856525
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.
Stray KM; Bam RA; Birkus G; Hao J; Lepist EI; Yant SR; Ray AS; Cihlar T
Antimicrob Agents Chemother; 2013 Oct; 57(10):4982-9. PubMed ID: 23896476
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters.
Kohler JJ; Hosseini SH; Green E; Abuin A; Ludaway T; Russ R; Santoianni R; Lewis W
Lab Invest; 2011 Jun; 91(6):852-8. PubMed ID: 21403643
[TBL] [Abstract][Full Text] [Related]
12. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.
Lee WA; He GX; Eisenberg E; Cihlar T; Swaminathan S; Mulato A; Cundy KC
Antimicrob Agents Chemother; 2005 May; 49(5):1898-906. PubMed ID: 15855512
[TBL] [Abstract][Full Text] [Related]
13. Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate.
Mizuno N; Takahashi T; Iwase Y; Kusuhara H; Niwa T; Sugiyama Y
Drug Metab Dispos; 2007 Aug; 35(8):1429-34. PubMed ID: 17502342
[TBL] [Abstract][Full Text] [Related]
14. Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent.
Ray AS; Vela JE; Boojamra CG; Zhang L; Hui H; Callebaut C; Stray K; Lin KY; Gao Y; Mackman RL; Cihlar T
Antimicrob Agents Chemother; 2008 Feb; 52(2):648-54. PubMed ID: 18056281
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity.
Bam RA; Yant SR; Cihlar T
Antivir Ther; 2014; 19(7):687-92. PubMed ID: 24699134
[TBL] [Abstract][Full Text] [Related]
16. Renal secretion of hydrochlorothiazide involves organic anion transporter 1/3, organic cation transporter 2, and multidrug and toxin extrusion protein 2-K.
Yin J; Wagner DJ; Prasad B; Isoherranen N; Thummel KE; Wang J
Am J Physiol Renal Physiol; 2019 Oct; 317(4):F805-F814. PubMed ID: 31322418
[TBL] [Abstract][Full Text] [Related]
17. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.
Imaoka T; Kusuhara H; Adachi M; Schuetz JD; Takeuchi K; Sugiyama Y
Mol Pharmacol; 2007 Feb; 71(2):619-27. PubMed ID: 17110501
[TBL] [Abstract][Full Text] [Related]
18. Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6).
Bleasby K; Hall LA; Perry JL; Mohrenweiser HW; Pritchard JB
J Pharmacol Exp Ther; 2005 Aug; 314(2):923-31. PubMed ID: 15914676
[TBL] [Abstract][Full Text] [Related]
19. Cl- -dependent upregulation of human organic anion transporters: different effects on transport kinetics between hOAT1 and hOAT3.
Ueo H; Motohashi H; Katsura T; Inui K
Am J Physiol Renal Physiol; 2007 Jul; 293(1):F391-7. PubMed ID: 17429031
[TBL] [Abstract][Full Text] [Related]
20. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Kiser JJ; Carten ML; Aquilante CL; Anderson PL; Wolfe P; King TM; Delahunty T; Bushman LR; Fletcher CV
Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
